Australian Clinical Labs Limited (ASX:ACL)

Australia flag Australia · Delayed Price · Currency is AUD
2.600
-0.030 (-1.14%)
Sep 5, 2025, 4:10 PM AEST
-1.14%
Market Cap505.61M
Revenue (ttm)741.27M
Net Income (ttm)32.43M
Shares Out194.47M
EPS (ttm)0.17
PE Ratio15.25
Forward PE13.50
Dividend0.13 (4.81%)
Ex-Dividend DateSep 1, 2025
Volume345,815
Average Volume1,525,335
Open2.640
Previous Close2.630
Day's Range2.590 - 2.650
52-Week Range2.470 - 3.860
Beta1.07
RSI42.39
Earnings DateAug 26, 2025

About Australian Clinical Labs

Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, including molecular cancer, harmony NIPT, genetic carrier screening and other antenatal, cardiac, and commercial drug and alcohol testing services; chemical pathology, haematology, histopathology and cytopathology, serology and microbiology, allergy and immunology, and veterinary and functional pathology services; pathology services for clinical trials; and CPD programs. It serves doctors, patients, and corporate clients. ... [Read more]

Sector Healthcare
Founded 2020
Employees 4,700
Stock Exchange Australian Securities Exchange
Ticker Symbol ACL
Full Company Profile

Financial Performance

In 2025, Australian Clinical Labs's revenue was 741.27 million, an increase of 6.45% compared to the previous year's 696.37 million. Earnings were 32.43 million, an increase of 35.50%.

Financial Statements

News

There is no news available yet.